BiPAP S/T-D30治疗慢性阻塞性肺疾病并肺性脑病的疗效分析

Clinical Effects of BiPAP S/T-D30 Therapy on Pulmonary Encephalopathy in COPD

目的:研究慢性阻塞性肺疾病(COPD)合并肺性脑病应用BiPAP S/T-D30呼吸机的治疗效果。方法:26例COPD合并肺性脑病患者随机分为BiPAP治疗组与常规治疗组,观察两组的治疗效果。结果:BiPAP组治疗前后比较pH、PaO_2、PacO_2、SaO_2有显著差异(P<0.01);常规组治疗前后比较PaO_2、SaO_2有差异(P<0.05),而pH、PaCO_2无显著差异(P>0.05)。结论:BiPAP能迅速改善病人的二氧化碳潴留及低氧血症,减轻症状,减少建立人工气道的可能性,是治疗COPD合并肺性脑病的无创性有效、方便、安全的方法。

Objective: To study the effects of BiPAP30 therapy on pulmonary encephalopthy in D-COPD. Methods: 26 patients with COP, D and pulmonary encephalopathy were divided randomly into BiPAP group and conventional treatment group. The results of our treatments were analyzed. Results: After BiPAP ventilation, we found that pH,PaO_2,PaCO_2,SaO_2 showed a statistical remarkable differences (P<0.01 ). While conventional treatment, only PaO_2, SaO_2 showed a statistical difference(P<0.05). Conclusion: BiPAP can improve hypercarbia and hypoxidosis and alleviate symptoms in these patients. At the same time, it can reduce the useness of endotrachea intubation. So it is a noninvasive effective and safe method for treatment of pulmonary encephalopathy in COPD.